Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
243 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hypercholesterolemia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hypercholesterolemia - Pipeline Review, H1 2016', provides an overview of the Hypercholesterolemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypercholesterolemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia - The report reviews pipeline therapeutics for Hypercholesterolemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hypercholesterolemia therapeutics and enlists all their major and minor projects - The report assesses Hypercholesterolemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hypercholesterolemia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Hypercholesterolemia Overview 7 Therapeutics Development 8 Hypercholesterolemia - Therapeutics under Development by Companies 10 Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes 14 Hypercholesterolemia - Pipeline Products Glance 15 Hypercholesterolemia - Products under Development by Companies 19 Hypercholesterolemia - Products under Investigation by Universities/Institutes 24 Hypercholesterolemia - Companies Involved in Therapeutics Development 25 Hypercholesterolemia - Therapeutics Assessment 61 Drug Profiles 76 Hypercholesterolemia - Recent Pipeline Updates 169 Hypercholesterolemia - Dormant Projects 217 Hypercholesterolemia - Discontinued Products 223 Hypercholesterolemia - Product Development Milestones 225 Appendix 234
List of Tables
Number of Products under Development for Hypercholesterolemia, H1 2016 16 Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H1 2016 17 Number of Products under Development by Companies, H1 2016 19 Number of Products under Development by Companies, H1 2016 (Contd..1) 20 Number of Products under Development by Companies, H1 2016 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H1 2016 22 Comparative Analysis by Late Stage Development, H1 2016 23 Comparative Analysis by Clinical Stage Development, H1 2016 24 Comparative Analysis by Early Stage Development, H1 2016 25 Comparative Analysis by Unknown Stage Development, H1 2016 26 Products under Development by Companies, H1 2016 27 Products under Development by Companies, H1 2016 (Contd..1) 28 Products under Development by Companies, H1 2016 (Contd..2) 29 Products under Development by Companies, H1 2016 (Contd..3) 30 Products under Development by Companies, H1 2016 (Contd..4) 31 Products under Investigation by Universities/Institutes, H1 2016 32 Hypercholesterolemia - Pipeline by 3SBio Inc., H1 2016 33 Hypercholesterolemia - Pipeline by Abeome Corporation, H1 2016 34 Hypercholesterolemia - Pipeline by Aegerion Pharmaceuticals, Inc., H1 2016 35 Hypercholesterolemia - Pipeline by AFFiRiS AG, H1 2016 36 Hypercholesterolemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 37 Hypercholesterolemia - Pipeline by Alvogen Korea Co., Ltd., H1 2016 38 Hypercholesterolemia - Pipeline by AtheroNova Inc., H1 2016 39 Hypercholesterolemia - Pipeline by BioLingus AG, H1 2016 40 Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016 41 Hypercholesterolemia - Pipeline by Cerenis Therapeutics Holding SA, H1 2016 42 Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 43 Hypercholesterolemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 44 Hypercholesterolemia - Pipeline by Daewon Pharm Co. Ltd., H1 2016 45 Hypercholesterolemia - Pipeline by Dybly AG, H1 2016 46 Hypercholesterolemia - Pipeline by Eli Lilly and Company, H1 2016 47 Hypercholesterolemia - Pipeline by Esperion Therapeutics, Inc., H1 2016 48 Hypercholesterolemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 49 Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 50 Hypercholesterolemia - Pipeline by Immune Response BioPharma, Inc., H1 2016 51 Hypercholesterolemia - Pipeline by Johnson & Johnson, H1 2016 52 Hypercholesterolemia - Pipeline by Kadmon Corporation, LLC, H1 2016 53 Hypercholesterolemia - Pipeline by Kastle Therapeutics, LLC, H1 2016 54 Hypercholesterolemia - Pipeline by Kowa Company, Ltd., H1 2016 55 Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 56 Hypercholesterolemia - Pipeline by Merck & Co., Inc., H1 2016 57 Hypercholesterolemia - Pipeline by Omeros Corporation, H1 2016 58 Hypercholesterolemia - Pipeline by Pfizer Inc., H1 2016 59 Hypercholesterolemia - Pipeline by Planet Biotechnology Inc., H1 2016 60 Hypercholesterolemia - Pipeline by Progenra, Inc., H1 2016 61 Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 62 Hypercholesterolemia - Pipeline by RegenxBio Inc., H1 2016 63 Hypercholesterolemia - Pipeline by Serometrix, LLC, H1 2016 64 Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 65 Hypercholesterolemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 66 Hypercholesterolemia - Pipeline by Viking Therapeutics, Inc., H1 2016 67 Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H1 2016 68 Assessment by Monotherapy Products, H1 2016 69 Assessment by Combination Products, H1 2016 70 Number of Products by Stage and Target, H1 2016 72 Number of Products by Stage and Mechanism of Action, H1 2016 77 Number of Products by Stage and Route of Administration, H1 2016 81 Number of Products by Stage and Molecule Type, H1 2016 83 Hypercholesterolemia Therapeutics - Recent Pipeline Updates, H1 2016 177 Hypercholesterolemia - Dormant Projects, H1 2016 225 Hypercholesterolemia - Dormant Projects (Contd..1), H1 2016 226 Hypercholesterolemia - Dormant Projects (Contd..2), H1 2016 227 Hypercholesterolemia - Dormant Projects (Contd..3), H1 2016 228 Hypercholesterolemia - Dormant Projects (Contd..4), H1 2016 229 Hypercholesterolemia - Dormant Projects (Contd..5), H1 2016 230 Hypercholesterolemia - Discontinued Products, H1 2016 231 Hypercholesterolemia - Discontinued Products (Contd..1), H1 2016 232
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
